

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

PROFIT WARNING

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of the directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) wish to inform the shareholders and potential investors of the Company that, based on the unaudited consolidated management accounts of the Company for the six months ended 30 June 2016 prepared in accordance with Hong Kong Financial Reporting Standards, the Group’s unaudited interim results for the six months ended 30 June 2016 is expected to record a slight loss, while the net profit for the six months ended 30 June 2015 is approximately HK\$280,300,000.

Turning from profit into loss is mainly due to decreases in sales volume and selling prices of the major intermediate product 6-APA and major bulk medicine product Amoxicillin during the period. Decrease in production lead to higher production costs and resulting significant decline in gross profit.

The information in this announcement is only based on the information currently available to the management. The results of the Group for the six months ended 30 June 2016 have not yet been finalised nor reviewed by the auditor and audit committee of the Company. The final results of the Group for the six months ended 30 June 2016 may be different to the information referred in this announcement.

Detailed unaudited interim results of the Group for the six months ended 30 June 2016 will be published in the forthcoming 2015 interim results announcement and interim report of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Tsoi Hoi Shan
Chairman

Hong Kong, 11 August 2016

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.